Bio-Rad Laboratories, Inc. (BIO) is scheduled to announce Q1 earnings results on Thursday, April 30th, after market close.

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today announced the ...

TheFly reported on April 7 that Citigroup lowered its rating on BIO from Buy to Neutral and reduced its price target from ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies, with the ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Roop K. Lakkaraju ...

With a market cap of $9.5 billion, Bio-Rad Laboratories, Inc. (BIO) operates in the healthcare and life sciences industry. The Hercules, California-based company develops and manufactures a wide range ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based ...

Bio-Rad is a "picks and shovels" company in the life sciences industry, but lacks standout growth, margins, or returns, and that has been largely true for more than two decades. Recent trends in the ...

Bio-Rad Laboratories stock (NYSE: BIO), a life science research and clinical diagnostic products company, has seen a 48% fall this year, significantly underperforming the broader S&P500 index, down 24 ...

Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2026 on Thursday, ...